Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Across the recent three months, 6 analysts have shared their insights on Vertex VERX, expressing a variety of opinions spanning from bullish to bearish. The table below offers a condensed view of ...

Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and welcome to the Vertex Inc. Third Quarter 2024 ...

Unlock Excel Copilot's potential for efficient data handling and insightful analysis with its latest powerful features. Excel ...

"Field Trial of Hydrogen Storage in Canadian Domal and Bedded Salts” has now received a total of $2.28 million in ...

Acadia Pharmaceuticals sold its priority review voucher for $150 million ... early-stage study results on its oral obesity ...

Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ETCompany ParticipantsJoe Crivelli - Vice President, ...

Vertex, Inc. (NASDAQ: VERX) ("Vertex" or the "Company"), a leading global provider of indirect tax solutions, today announced financial results ...

Vertex will receive 60% and Crispr will receive 40% of ... which contributed to its withdrawal from the EU and UK markets. After a review of additional clinical data, the FDA approved Zynteglo in ...

Vertex is approaching two key PDUFA dates in January for new treatments in cystic fibrosis and pain respectively.

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $4.38 per share for the third quarter of 2024, ...